Haiden A. Huskamp, Ph.D. is a professor of health care policy. Her research is focused in three primary areas: 1) mental health policy; 2) prescription drug policy; and 3) the financing and utilization of end-of-life care services.
Dr. Huskamp has developed a body of research on the impact of pharmacy management tools used to control drug costs on drug utilization, cost, and quality of care. She has written numerous papers on the Medicare Part D drug benefit and its implications for vulnerable populations, including individuals with a mental illness and nursing home residents. She currently serves as Principal Investigator for an R01 funded by the National Institute on Aging to examine the impact of Medicare Part D plan generosity on health outcomes among nursing home residents. She recently completed a Career Development Award from the National Institute of Mental Health focused on the economics of psychotropic medications. Through this award, she examined the impact of three-tier prescription drug formularies on cost and utilization patterns for drugs used to treat mental illness; the effect of generic entry of antidepressant medications on drug sales, market share, and advertising and promotional strategies of antidepressant manufacturers; and the implications of the Medicare Part D drug benefit for access to psychotropic medications and incentives for future psychotropic innovation. Through a Robert Wood Johnson Foundation Investigator Award in Health Policy Research, Dr. Huskamp is currently comparing the social costs and benefits of newer psychotropic drugs to assess their social value and identify ways that the value of psychotropic drug spending can be increased. She currently serves as a member of the Institute of Medicine Committee on Accelerating Rare Diseases Research and Orphan Products Development.
Dr. Huskamp has assessed the effect of implementing comprehensive mental health parity (i.e., requiring plans to offer the same level of coverage for mental health and general medical services) in the Federal Employees Health Benefits Program on use of mental health services, total and out-of-pocket mental health costs, and the likelihood of receiving appropriate treatment. She currently serves as Principal Investigator for an R01 funded by the National Institute of Mental Health on the effect of mental health parity on individuals with severe mental illnesses and high mental health service costs. Dr. Huskamp has published numerous papers on the impact of managed care for mental health services on utilization patterns, costs and quality of care.
Dr. Huskamp recently completed a study of factors associated with discussing hospice care with a physician among metastatic lung cancer patients through funding provided by the National Cancer Institute and the Department of Veterans Affairs. Other recent work on end-of-life care includes a study of patient-level variation in hospice costs funded by the Agency for Healthcare Research and Quality and the Alfred P. Sloan Foundation, and a study of patient and nursing home factors that contribute to earlier referrals to hospice among terminally-ill nursing home residents funded by the Charles H. Farnsworth Trust. Dr. Huskamp previously served as a member of the Institute of Medicine Committee on Care for Children Who Die and Their Families.
Dr. Huskamp received her BA in public policy from Duke University and her PhD in health policy with a concentration in economics from Harvard University.
Dr. Huskamp has developed a body of research on the impact of pharmacy management tools used to control drug costs on drug utilization, cost, and quality of care. She has written numerous papers on the Medicare Part D drug benefit and its implications for vulnerable populations, including individuals with a mental illness and nursing home residents. She currently serves as Principal Investigator for an R01 funded by the National Institute on Aging to examine the impact of Medicare Part D plan generosity on health outcomes among nursing home residents. She recently completed a Career Development Award from the National Institute of Mental Health focused on the economics of psychotropic medications. Through this award, she examined the impact of three-tier prescription drug formularies on cost and utilization patterns for drugs used to treat mental illness; the effect of generic entry of antidepressant medications on drug sales, market share, and advertising and promotional strategies of antidepressant manufacturers; and the implications of the Medicare Part D drug benefit for access to psychotropic medications and incentives for future psychotropic innovation. Through a Robert Wood Johnson Foundation Investigator Award in Health Policy Research, Dr. Huskamp is currently comparing the social costs and benefits of newer psychotropic drugs to assess their social value and identify ways that the value of psychotropic drug spending can be increased. She currently serves as a member of the Institute of Medicine Committee on Accelerating Rare Diseases Research and Orphan Products Development.
Dr. Huskamp has assessed the effect of implementing comprehensive mental health parity (i.e., requiring plans to offer the same level of coverage for mental health and general medical services) in the Federal Employees Health Benefits Program on use of mental health services, total and out-of-pocket mental health costs, and the likelihood of receiving appropriate treatment. She currently serves as Principal Investigator for an R01 funded by the National Institute of Mental Health on the effect of mental health parity on individuals with severe mental illnesses and high mental health service costs. Dr. Huskamp has published numerous papers on the impact of managed care for mental health services on utilization patterns, costs and quality of care.
Dr. Huskamp recently completed a study of factors associated with discussing hospice care with a physician among metastatic lung cancer patients through funding provided by the National Cancer Institute and the Department of Veterans Affairs. Other recent work on end-of-life care includes a study of patient-level variation in hospice costs funded by the Agency for Healthcare Research and Quality and the Alfred P. Sloan Foundation, and a study of patient and nursing home factors that contribute to earlier referrals to hospice among terminally-ill nursing home residents funded by the Charles H. Farnsworth Trust. Dr. Huskamp previously served as a member of the Institute of Medicine Committee on Care for Children Who Die and Their Families.
Dr. Huskamp received her BA in public policy from Duke University and her PhD in health policy with a concentration in economics from Harvard University.
Learn more about Dr. Huskamp's work by viewing the following featured articles on 10/4/10, 12/10/08, 10/8/08 and news briefs on 2/12/13, 7/21/12, 8/24/11, 2/25/11, 1/13/10, 5/28/09, 5/5/09, 9/28/07, 3/27/07, 4/7/06.